Table 2 Fifteen uncontrolled clinical studies with nitroxoline in 947 adult patients of both genders
First author | Year | Pat (n) | Indication (T/P) | Dosage | Duration | Success rate | Adverse events |
|---|---|---|---|---|---|---|---|
Kuss [43] | 1962 | 72 | T: acute cUTI & uUTI | 400 mg/d | 20–45 days | 78% | 1.3% gastrointestinal |
Moreau [44] | 1962 | 20 | T: acute cUTI | 400–500 mg/d | 8–10 (−45) days | 90% | 5% gastrointestinal |
v. Rütte [45] | 1969 | 200 | P: chronic rUTI | 300–500 mg/d | 2–3 months | 80% | 0% |
shortly 800 mg/d | 1 day | ||||||
Uhlir [46] | 1972 | 20 | T: acute UTI (7), chronic PN (13) | 300 mg/d | 14 days | 100% | 0% |
Allal [47] | 1973 | 264 | T: UTI during pregnancy | 300 mg/d | 6 days | > 75% | No data |
Bittard [48] | 1974 | 50 | P: post-op. catheter | 7.5–10 mg/kg/d | 6 weeks | 92% | Few gastrointestinal |
Schlesinger [49] | 1975 | 65 | T: chronic PN (62), chronic prostatitis (3) | 300–500 mg/d | 10 days | 80% clinical | 0% |
Aubert [50] | 1976 | 28 | T: post-op. catheter, after endoscopy | 200–300 mg/d | 10–15 days | 72% | 0% |
Dufour [51] | 1979 | 15 | T: acute prostatitis | 900–1600 mg/d | 3–5 days | 81% | No data |
Lenzner [52] | 1983 | 60 | T: fungal UTI | 750 mg/d | 10–20 days | 80% | 3.3% itching; few cases with nausea and vomiting |
Schülke [53] | 1984 | 50 | T: postop., acute UTI after removal of urethral catheter for 3–10 days | 750 mg/d | 3 days | 78% | 0% |
Sachse [54] | 1984 | 44 | P: chronic rUTI | 750 mg/d | 4 months | 77% free of rUTI; rUTI rate decreased from 0.33 to 0.11/month | 9% gastrointestinal 2.2% exanthema |
Demontrond [55] | 1986 | 15 | T: candiduria in hospitalised patients | 600 mg/d | 10–30 days | 87% | 0% |
Frobert [56] | 1987 | 36 | T: acute, uUTI in hospitalised patients | 600 mg/d | 10 days | 93% bacteriological | 5.5% gastrointestinal |
87% clinical | 2.7% nausea | ||||||
2.7% dizziness | |||||||
Cancet [27] | 1987 | 8 | T: urogenital fungal infections | 600 mg/d | 15 days | 100% | no data |